passages: 1220
passages: document
passages: Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast : a randomised controlled trial investigating the effects on airway inflammation in asthma . BACKGROUND Few studies have compared treatment strategies in patients with asthma poorly controlled on low dose inhaled corticosteroids , and little is known about the effects of different treatments on airway inflammation . In this double-blind , placebo-controlled , parallel group study , we compared the effects of salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC ) and FP plus montelukast ( FP/M ) on sputum inflammatory markers , airway responsiveness , lung function , and symptoms in adult asthmatics . METHODS Sixty-six subjects were randomised to SFC or FP/M for 12 weeks . The primary outcome was changes in neutrophil , eosinophil , macrophage , lymphocyte , and epithelial cell levels in induced sputum . Additional outcomes included the change in other sputum markers of airway inflammation , airway responsiveness , symptom control , and lung function . RESULTS Both treatments had no significant effect on induced sputum inflammatory cells , although there was a trend for a reduction in sputum eosinophils . Both treatments significantly improved airway responsiveness , whereas SFC generally led to greater improvements in symptom control and lung function than FP/M . FP/M led to significantly greater reductions in sputum cysteinyl leukotrienes than SFC ( treatment ratio 1.80 ; 95 % CI 1.09 , 2.94 ) . CONCLUSION Both treatments led to similar control of eosinophilic airway inflammation , although PEF and symptom control were better with SFC . STUDY NUMBER : SAM40030 ( SOLTA ) .
entities: 1221
entities: Intervention_Pharmacological
entities: Salmeterol
entities: 1222
entities: Intervention_Pharmacological
entities: fluticasone propionate
entities: 1223
entities: Intervention_Pharmacological
entities: fluticasone propionate
entities: 1224
entities: Intervention_Pharmacological
entities: montelukast :
entities: 1225
entities: Intervention_Pharmacological
entities: salmeterol
entities: 1226
entities: Intervention_Pharmacological
entities: fluticasone propionate ( FP ) ( Seretide ; SFC )
entities: 1227
entities: Intervention_Pharmacological
entities: FP
entities: 1228
entities: Intervention_Pharmacological
entities: montelukast ( FP/M )
entities: 1229
entities: Intervention_Pharmacological
entities: SFC
entities: 1230
entities: Intervention_Pharmacological
entities: FP/M
entities: 1231
entities: Intervention_Pharmacological
entities: SFC
entities: 1232
entities: Intervention_Pharmacological
entities: FP/M . FP/M
entities: 1233
entities: Intervention_Pharmacological
entities: SFC
entities: 1234
entities: Intervention_Pharmacological
entities: SFC .
entities: 1235
entities: Outcome_Physical
entities: airway inflammation
entities: 1236
entities: Outcome_Physical
entities: sputum inflammatory markers
entities: 1237
entities: Outcome_Physical
entities: airway responsiveness , lung function
entities: 1238
entities: Outcome_Physical
entities: symptoms
entities: 1239
entities: Outcome_Physical
entities: changes in neutrophil , eosinophil , macrophage , lymphocyte , and epithelial cell levels in induced sputum .
entities: 1240
entities: Outcome_Physical
entities: change in other sputum markers of airway inflammation , airway responsiveness , symptom control , and lung function .
entities: 1241
entities: Outcome_Physical
entities: sputum inflammatory
entities: 1242
entities: Outcome_Physical
entities: sputum eosinophils .
entities: 1243
entities: Outcome_Physical
entities: airway responsiveness
entities: 1244
entities: Outcome_Physical
entities: symptom control and lung function
entities: 1245
entities: Outcome_Physical
entities: sputum cysteinyl leukotrienes
entities: 1246
entities: Outcome_Physical
entities: eosinophilic airway inflammation
entities: 1247
entities: Participant_Condition
entities: patients with asthma
entities: 1248
entities: Participant_Age
entities: adult
entities: 1249
entities: Participant_Condition
entities: asthmatics .
entities: 1250
entities: Participant_Sample-size
entities: Sixty-six subjects